The US Food and Drug Administration (FDA) has approved Sagent Pharmaceuticals' Haloperidol Injection, USP to treat schizophrenia.
Haloperidol Injection, USP is also indicated for the control of tics and vocal utterances of Tourette’s disorder.
Sagent’s haloperidol injection will be offered in 5mg per ml single-dose and 50mg per 10 ml multi-dose, latex-free vials.
Sagent’s haloperidol features the company’s reventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
The company anticipates to launch the product in the fourth quarter of 2011.